PATENT CLAIM ANALYSIS

Application Number: 16082765
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-02
Patent Classification: ["514", "407000"]

Abstract:
This invention relates to a novel dosage regimen for administration of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof, namely in the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD).

Claim (Index 41):
The method of  claim 40 , wherein a third oral dose of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide or a pharmaceutically acceptable derivative thereof is in the range of 10 mg-50 mg.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 97.0
- Lexical Diversity: 1.13158
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['16082772', '14386174', '11426693', '14088093', '14622560']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7553182205162325
- 35 USC 102 Novelty (BERT): 0.6093356919410137
- Combined Prediction Score: 0.7407199676587106
- Mean Citation Score: 341.435718
- Max Citation Score: 561.3712
- Similarity Product: 453.96119538517

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test